Boehringer Ingelheim eyes MASH as the next front for survodutide

Boehringer Ingelheim eyes MASH for survodutide after Phase 3 liver-fat reductions, as new approvals shift the field beyond weight loss. “We have a program in MASH, in the liver, the LIVERAGE program , plus a robust data-generation program to come over the next couple of years, because we want to bring a comprehensive package for metabolic health,” said Neeraja Balachander, who oversees the company’s cardio-renal-metabolic portfolio. LIVERAGE is Boehringer’s Phase 3 program in adults with MASH and fibrosis. Beyond MASH, the headline survodutide readout is its obesity trial. In SYNCHRONIZE-1 , a 76-week Phase 3 study published June 7 in…

For decades, fatty liver disease and its more serious inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), were often overlooked conditions with few approved treatments. Boehringer Ingelheim is among the companies now going after them with a concerted push. “We have a program in MASH, in the liver, the LIVERAGE program, plus a robust data-generation program to…

The post Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist appeared first on Drug Discovery and Development.